Multiple myeloma trials in India
5 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Ahmedabad, Belagavi, Gurugram, Ludhiana, Madurai, Mumbai, Puducherry, Varanasi
- Age
- 18 years and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - Phase 2Taking peopleLess Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
- Where
- Navi Mumbai
- Age
- 18 years and over
- People
- 52
- Run by
- Tata Memorial Centre
See details and how to joinNCT07891923 - Phase 3Taking peopleA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Bengaluru, Gūrgaon, Jaipur, Kolkata, New Delhi, Pune
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07518186 - Phase 3Taking peopleA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Ahmedabad, Bangalore, Hyderabad, Kolkata, Pune, Sushrut Hospital and Research
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00 - Phase 1Taking peopleStudy of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- Where
- Bangalore, Gandhinagar, Hyderabad, Pune
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- Ichnos Sciences SA
See details and how to joinNCT05862012 · EU 2023-507071-21-01